Gyre Therapeutics, Inc. (GYRE)
NASDAQ · Manufacturing · Pharmaceutical preparations
GYRE price, last 12 months
Key stats
- Previous close
- $7.33
- Open
- $7.39
- Day range
- $7.13 – $7.42
- 52-week range
- $5.44 – $9.42
- Volume
- 134.8K
- Avg volume (20 days)
- 184.4K
- Market cap
- $779.3M
Performance
Technicals and fundamentals
About Gyre Therapeutics, Inc.
Gyre Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of small-molecule therapies for the treatment of organ fibrosis and inflammatory diseases. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.
- Sector
- Manufacturing
- Industry
- Pharmaceutical preparations
- Listed on
- NASDAQ
- Market cap
- $779.3M